| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. | Lancet Oncol | 2014 | 4.52 |
| 2 | Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome. | Oncotarget | 2016 | 0.75 |